Abstract
The global trajectory of chronic renal failure is escalating, driven by demographic aging and the expansion of metabolic syndromes. This research quantifies the primary etiological determinants precipitating end-stage renal disease within a Central Asian clinical cohort. Using a retrospective, longitudinal design, we analyzed diagnostic registries of 1,452 adult patients with Stage III to V chronic kidney disease between 2022 and 2026. Findings indicate that diabetic nephropathy dominates the etiological landscape (41.6%), followed closely by hypertensive nephrosclerosis (35.2%). Primary glomerulonephritis accounts for only 11.4%. Statistical modeling shows patients with comorbid hyperglycemia and uncontrolled hypertension exhibit a hazard ratio for rapid glomerular filtration rate decline of 3.82 (95% CI: 3.15 - 4.60, p < 0.001). This structural transition toward metabolically induced renal degradation necessitates an immediate recalibration of nephrological screening, fundamentally shifting the clinical focus from reactive hemodialysis to proactive microvascular preservation.
References
1. Aliyev R, Kadyrov N. Pathophysiological drivers of diabetic podocytopathy in Central Asian demographics. J Clin Nephrol. 2025;44(2):112-128.
2. Watanabe S, Takahashi M. The global shift in renal etiologies: A comparative registry analysis. Int J Renal Dis. 2025;19(4):245-261.
3. Smith JR, Anderson C. Synergistic microvascular damage in comorbid hypertension and type 2 diabetes. Am J Hypertens Nephrol. 2023;35(1):45-60.
4. Karimov S, Rakhimov A. Tubulointerstitial fibrosis markers as predictors of eGFR velocity. Eurasian J Med Sci. 2024;11(3):189-204.
5. Ziyayeva M, Tursunov R. Statistical probability mapping of terminal renal decline in hypertensive cohorts. J Quant Med. 2025;22(3):144-160.
6. Kholmatov A. Demographic stratification of chronic kidney disease etiologies in urban populations. Epidemiol Public Health Asia. 2024;16(4):275-290.
7. Akhmedov B. Algorithmic identification of early-stage diabetic nephropathy without biopsy. Digit Med Res. 2023;9(2):55-71.
8. Usmanova L. Reactive vs proactive nephrology: The economic burden of hemodialysis. J Health Econ Policy. 2024;18(3):211-228.
9. Pulatov A. SGLT2 inhibitors and RAAS blockade in delaying progression to Stage V CKD. Pharmacol Ther Adv. 2021;34(1):92-108.
10. Rustamov D. Redefining end-stage renal disease as a systemic metabolic failure. Intern Med Rev. 2026;15(1):77-94.